ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1945 • ACR Convergence 2021

    Efficacy of Upadacitinib on Psoriatic Arthritis with Axial Involvement Defined by Investigator Assessment and PRO-Based Criteria: Results from Two Phase 3 Studies

    Xenofon Baraliakos1, Roberto Ranza2, Andrew Ostor3, Francesco Ciccia4, Laura Coates5, Simona Rednic6, Jessica Walsh7, Tianming Gao8, Apinya Lertratanakul8, In-Ho Song8, Fabiana Ganz8, Kevin Douglas8 and Atul Deodhar9, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 2Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlandia, MG, Brazil, 3Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia, 4University of Campania Luigi Vanvitelli, Napoli, Italy, 5Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 6Emergency Clinical County Hospital, Rheumatology and Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania, 7Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, 8AbbVie Inc., North Chicago, IL, 9Oregon Health & Science University, Portland, OR

    Background/Purpose: Patients with PsA and axial involvement have higher disease activity and greater reductions in quality of life;1 however, there are no accepted criteria for…
  • Abstract Number: PP02 • ACR Convergence 2021

    Leveraging Digital Health Tracking to Improve Arthritis Management

    Katie Roberts, Annapolis, MD

    Background/Purpose: I was diagnosed with psoriasis when I was age 10 in 1986. At that time, my treatment plan consisted of regular application of Eucerin…
  • Abstract Number: PP01 • ACR Convergence 2021

    Unicycling for a Cure: My UNIque Physical Activity Intervention for Rheumatoid Arthritis During the COVID19 Pandemic

    Dana Guglielmo, San Diego, CA

    Background/Purpose: I was diagnosed with rheumatoid arthritis at age 17. In my 20s, I joined Racing For A Cure of the Arthritis National Research Foundation,…
  • Abstract Number: 1946 • ACR Convergence 2021

    Therapeutic Drug Monitoring Compared to Standard Infliximab Therapy in Patients with Immune-mediated Inflammatory Diseases: A Randomized Controlled Trial

    Silje Watterdal Syversen1, Guro Goll1, Kristin Jørgensen2, Marthe Brun1, Øystein Sandanger3, Kristin Hammersbøen2, Joseph Sexton1, Inge Olsen3, Johanna Gehin4, David Warren3, Rolf Anton Klaasen3, Trude Bruun5, Maud Kristine Ljoså6, Anne Haugen7, Rune Njålla8, Brigitte Michelsen9, Camilla Zettel10, Yngvill Bragenes11, Svanaug Skorpe12, Eldri Strand13, Pawel Mielnik14, Cato Mørk15, Tore Kvien1, Jørgen Jahnsen2, Nils Bolstad16 and Espen Haavardsholm1, 1Diakonhjemmet Hospital, Oslo, Norway, 2Akershus University Hospital, Lørenskog, Norway, 3Oslo University Hospital, Oslo, Norway, 4Oslo University Hospital, Lillehammer, Nepal, 5The University Hospital of North Norway, Tromsø, Norway, 6Dept. of Rheumatology, Ålesund Hospital, Ålesund, Norway, 7Østfold Hospital Trust, Moss, Norway, 8Nordland Hospital Trust, Bodø, Bodø, Norway, 9Hospital of Southern Norway Trust, Kristiansand, Norway, 10Betanien Hospital, Skien, Norway, 11Vestre Viken Hospital Trust, Drammen, Norway, 12Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, 13Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, 14Førde Hospital Trust, Førde, Norway, 15Akershus Dermatology Center, Lørenskog, Norway, 16Oslo University Hospital, Radiumhospitalet, Oslo, Norway

    Background/Purpose: Proactive therapeutic drug monitoring (TDM), a treatment strategy based on scheduled assessments of serum drug levels, has been proposed to optimize efficacy and safety…
  • Abstract Number: PP05 • ACR Convergence 2021

    Fighting Health-Related Misinformation Using Social Media / How Creating an Online Group for Patients with Relapsing Polychondritis — and Moderating It with Health Professionals — Helps Spread Reliable and Empowering Information

    Michael Linn1, Spenser Mestel2 and Susie Ratledge3, 1Relapsing Polychondritis Foundation, New York, NY, 2New York, NY, 3Relapsing Polychondritis: Secular Science and Support group, Chattanooga, TN

    Background/Purpose: Before I became ill in 2017, I was a registered nurse with a degree in health science who'd often educate patients about how they…
  • Abstract Number: PP08 • ACR Convergence 2021

    Should I Get the COVID-19 Vaccine With My RA? Using Evidence-Based Resources for Decision-Making

    Aberdeen Allen, Colgate Palmolive, Parlin, NJ

    Background/Purpose: Patients with autoimmune rheumatic diseases have concerns about getting the COVID-19 vaccine. As vaccines began to receive emergency use authorization, individuals with conditions like…
  • Abstract Number: PP07 • ACR Convergence 2021

    How Online Spanish-Language Resources Got Me and My RA Through the COVID-19 Pandemic

    Wigna Cruz, Puerto Rico

    Background/Purpose: I was experiencing joint pain especially in my wrists, which led me to see my physician for testing. Initially I was misdiagnosed with lupus.…
  • Abstract Number: PP04 • ACR Convergence 2021

    Dual Roles: Thriving with SLE as a Medical Student

    Chieh Lo1 and Song-Chou Hsieh2, 1School of Medicine, I-Shou Univerity, Kaohsiung, Taiwan (Republic of China), 2Division of Immunology, Allergy and Rheumatology, Department of Medicine, National Taiwan University Hospital, Taipei, Taiwan (Republic of China)

    Background/Purpose: A few days after my 18th birthday, I walked into a rheumatology clinic for the first time. I had ulcers in my mouth, felt…
  • Abstract Number: 1932 • ACR Convergence 2021

    Identifying Clusters of Longitudinal Autoantibody Profiles Associated with Systemic Lupus Erythematosus Disease Outcomes

    May Choi1, Irene Chen2, Ann Clarke3, Marvin Fritzler3, Katherine Buhler3, Murray Urowitz4, John Hanly5, Caroline Gordon6, Yvan St.Pierre7, Sang-Cheol Bae8, Juanita Romero-Diaz9, Francisco Sanchez-Guerrero10, Sasha Bernatsky11, Daniel Wallace12, David Isenberg13, Anisur Rahman14, Joan Merrill15, Paul R Fortin16, Dafna Gladman17, Ian N. Bruce18, Michelle Petri19, Ellen Ginzler20, Mary Anne Dooley21, Rosalind Ramsey-Goldman22, Susan Manzi23, Andreas Jnsen24, Graciela Alarcn25, Ronald van Vollenhoven26, Cynthia Aranow27, Meggan Mackay27, Guillermo Ruiz-Irastorza28, S Sam Lim29, Murat Inanc30, Kenneth Kalunian31, Sren Jacobsen32, Christine Peschken33, Diane Kamen34, Anca Askanase35, David Sontag2 and Karen Costenbader36, 1Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, 2Massachusetts Institute of Technology, Cambridge, MA, 3University of Calgary, Calgary, AB, Canada, 4Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, ON, Canada, 5Dalhousie University, Halifax, NS, Canada, 6Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, 7Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 8Hanyang University Medical Center, Seoul, Republic of Korea, 9Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Federal District, Mexico, 10University Health Network/Sinai Health system, Toronto, ON, Canada, 11McGill University, Montréal, QC, Canada, 12Cedars-Sinai, Los Angeles, CA, 13Centre for Rheumatology, University College London, London, United Kingdom, 14University College London, London, United Kingdom, 15Oklahoma Medical Research Foundation, Oklahoma City, OK, 16CHU de Quebec - Universite Laval, Québec City, QC, Canada, 17Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 18University of Manchester, Manchester, United Kingdom, 19Johns Hopkins University School of Medicine, Baltimore, MD, 20SUNY Downstate Health Sciences University, Brooklyn, NY, 21Raleigh Neurology Associates, Chapel Hill, NC, 22Northwestern University, Chicago, IL, 23Allegheny Health Network, Wexford, PA, 24Lund University, Lund, Sweden, 25University of Alabama at Birmingham, Birmingham, AL, 26Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, 27Feinstein Institutes for Medical Research, Manhasset, NY, 28Hospital Universitario Cruces, University of the Basque Country, Bizkaia, Spain, 29Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, 30Istanbul University Faculty of Medicine, Istanbul, Turkey, 31UC San Diego, La Jolla, CA, 32Copenhagen Lupus and Vasculitis Clinic, Centre for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, 33University of Manitoba, Winnipeg, MB, Canada, 34Medical University of South Carolina, Charleston, SC, 35Columbia University Medical Center, New York, NY, 36Brigham and Women's Hospital, Belmont, MA

    Background/Purpose: Prior studies of SLE clusters based on autoantibodies have utilized cross-sectional data from single centers. We applied clustering techniques to longitudinal and comprehensive autoantibody…
  • Abstract Number: 1911 • ACR Convergence 2021

    Patient’s and Rheumatologist’s Perspectives on the Burden of Adverse Drug Reactions Attributed to Biologics: A Qualitative Study

    Henrike Westerink1, Leanne Kosse2, Naomi Jessurun2, Astrid van Tubergen3, Harald Vonkeman4, Mike Nurmohamed5, Bart van den Bemt6 and Marieke de Vries7, 1Netherlands Pharmacovigilance Centre Lareb, Nijmegen, Netherlands, 2Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, Netherlands, 3Maastricht UMC+, Maastricht, Netherlands, 4Medisch Spectrum Twente; University of Twente, Enschede, Netherlands, 5Reade; Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, 6Sint Maartenskliniek; Radboud University Medical Center, Ubbergen, Netherlands, 7Radboud University Medical Centre, Nijmegen, Netherlands

    Background/Purpose: Previous studies showed a discrepancy between patient’s and HealthCare Professional (HCP) perspective on the burden of Adverse Drug Reactions (ADRs), where HCPs often underestimate…
  • Abstract Number: PP13 • ACR Convergence 2021

    CreakyKitchen: How the Online Cooking Show I Started is Building Community and Encouraging Better Food Choices for Me and Others Living with Rheumatic and Chronic Disease

    Chantelle Marcial, Boston, MA

    Background/Purpose: At 19, I was mis-diagnosed with Lupus as it was a common condition in my family. My treatment at that time was mainly DMARDs,…
  • Abstract Number: PP12 • ACR Convergence 2021

    Fighting for the Care We Deserve: My Experience as a Latina Patient-Researcher During the COVID-19 Pandemic

    Guadalupe Torres1, Courtney Wells2 and Kristine Carandang3, 1, 2University of Wisconsin-River Falls, School of Social Work, St. Paul, MN, 3Global Healthy Living Foundation, CreakyJoints, San Diego, CA

    Background/Purpose: I am a 23-year-old first generation Latina with rheumatoid arthritis (RA). Despite being disproportionately affected by rheumatic conditions, the perspectives of Latinx remain poorly…
  • Abstract Number: PP10 • ACR Convergence 2021

    Discovering ‘I’ Through Interaction with Support Group Members: A Place of Empathy That Transcends the Limitations of Words

    Noriko Okochi1, Eiji Oishi2 and Mika Ishiguro1, 1Rheumatic Disease and Vasculitis Support Network Japan, Tokyo, Japan, 2Rheumatic Disease and Vasculitis Support Network Japan, Yamaguchi, Japan

    Background/Purpose: Since 5-year-old, I have had unexplained symptoms. At the age of 13, my whole body became inflamed. The pain was so intense that I…
  • Abstract Number: PP09 • ACR Convergence 2021

    Family Planning while Living with Rheumatoid Arthritis

    Shannan O'Hara-Levi, Monroe, NY

    Background/Purpose: Over the course of my 30+ years living with Polyarticular Juvenile Rheumatoid Arthritis, I have never had long term success on any one biologic treatment,…
  • Abstract Number: 1811 • ACR Convergence 2021

    Efficacy of Guselkumab Across BASDAI Components in Treating Axial-Related Symptoms of Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-controlled Studies

    Frank Behrens1, Philip Mease2, Philip S Helliwell3, May Shawi4, Wim Noel5, Soumya Chakravarty6, Alexa Kollmeier7, Xie Xu8, Stephen Xu8, Yanli Wang8 and Xenofon Baraliakos9, 1CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine & Pharmacology, Goethe University Hospital, Frankfurt, Germany, 2Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 3Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 4Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, 5Janssen Pharmaceutica, Vilvoorde, Belgium, 6Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, 7Janssen Research & Development, LLC, La Jolla, CA, 8Janssen Research & Development, LLC, Spring House, PA, 9Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany

    Background/Purpose: Guselkumab (GUS), an anti-interleukin-23p19 subunit monoclonal antibody, is approved to treat psoriatic arthritis (PsA). Post hoc analyses of DISCOVER-1&2 suggested that GUS may be…
  • « Previous Page
  • 1
  • …
  • 639
  • 640
  • 641
  • 642
  • 643
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology